A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/ quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type.
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus)
A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)
A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
A phase III randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia
Real-world performance evaluation of PreSize Neurovascular medical software in a clinical setting
MND Register for England, Wales and Northern Ireland
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
Neurological Long-term Conditions: Online Integrated Care Platform Study
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
NIHR Mental Health BioResource for Depression and Anxiety
Developing the Clinical Anxiety Screen for people with Severe to Profound Intellectual Disabilities (CIASP-ID)
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
MND Register for England, Wales and Northern Ireland
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
MND Register for England, Wales and Northern Ireland
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
NIHR Mental Health BioResource for Depression and Anxiety
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
MND Register for England, Wales and Northern Ireland
MND Register for England, Wales and Northern Ireland
Systemic inflammation and the blood-brain barrier in multiple sclerosis.
MND Register for England, Wales and Northern Ireland
NIHR Mental Health BioResource for Depression and Anxiety
NIHR Mental Health BioResource for Depression and Anxiety
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
NIHR Mental Health BioResource for Depression and Anxiety
Developing the Clinical Anxiety Screen for people with Severe to Profound Intellectual Disabilities (CIASP-ID)
OptiCALS: A Randomised Controlled Trial with parallel Process Evaluation and Health Economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with Amyotrophic Lateral Sclerosis
NIHR Mental Health BioResource for Depression and Anxiety
Shortening Duration of Untreated Illness in First Episode Eating Disorders: A Randomised Controlled Feasibility Trial of a Smart-Phone Friendly Multi-Modal Decision Making Tool (FREED-Mobile; FREED-M) to Improve Help-Seeking
MND Register for England, Wales and Northern Ireland
NIHR Mental Health BioResource for Depression and Anxiety